Download Files:
Clopidogrel
$50 – $55
Products Details
Product Description
– Clopidogrel is an orally active platelet inhibitor that targets P2Y12 receptor. Clopidogrel is used to inhibit blood clots in coronary artery disease, peripheral vascular disease, and cerebrovascular disease.
Web ID
– HY-15283
Storage Temperature
– -20°C (Powder, stored under nitrogen, away from moisture)
Shipping
– Blue Ice
Applications
– Neuroscience-Neuromodulation
Molecular Formula
– C16H16ClNO2S
Citations
– ACS Nano. 2023 Mar 27.|Drug Des Devel Ther. 2020 Dec 21;14:5599-5610.|Front Pharmacol. 2022 Jan 10;12:792263.|Int J Biol Sci. 2019 Jan 1;15(1):239-252.|Int J Mol Sci. 2022, 23(16), 9118.|J Appl Physiol (1985). 2021 Sep 30.|J Pharm Health Care Sci. 2021 May 4;7(1):18.|Open Chem. 2020 Jun.|Research Square Preprint. 2023 Nov 14.|Theranostics. 2023; 13(6):2040-2056.|Thromb Res. 2023 May 8.|ACS Omega. 2020 Aug 4;5(32):19995-20003.|Am J Transl Res. 2020 May 15;12(5):1741-1753.|Foods. 2023 Feb 10;12(4):777.|J Food Biochem. 2020 Sep;44(9):e13352.
References
– [1]Zongyu Zheng, et al. Clopidogrel Reduces Fibronectin Accumulation and Improves Diabetes-Induced Renal Fibrosis. Int J Biol Sci. 2019 Jan.|[2]An insight into the interaction between clopidogrel and proton pump inhibitors By Shah, Bhavik S.; Parmar, Sanjay A.; Mahajan, Shailaja; Mehta, Anita A. From Current Drug Metabolism (2012), 13(2),225-235.
CAS Number
– 113665-84-2
Molecular Weight
– 321.82
Compound Purity
– 99.57
SMILES
– ClC1=C(C=CC=C1)[C@H](N2CCC3=C(C2)C=CS3)C(OC)=O
Clinical Information
– Launched
Research Area
– Cardiovascular Disease; Cancer
Solubility
– DMSO : 50 mg/mL (ultrasonic)
Target
– P2Y Receptor
Isoform
– P2Y12 Receptor
Pathway
– GPCR/G Protein
Product type
– Reference compound
Disclaimer: All products are for research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation.
